Medicover AB
F:5M0B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Medicover AB
F:5M0B
|
SE |
|
Guzman Y Gomez Ltd
OTC:GYGLF
|
AU |
Medicover AB
Medicover AB is a private healthcare and diagnostics company that runs clinics, hospitals, specialty centers, and medical labs. It serves patients directly, as well as employers, insurers, and other healthcare providers that buy testing or care for their members and employees. The company’s main services are doctor visits, specialist treatment, preventive care, fertility and women’s health services, and lab and imaging tests. Medicover makes money in two main ways: patients pay out of pocket or through insurance for medical visits and procedures, and business customers pay for diagnostic testing and corporate health plans. Its diagnostics business also sells lab services to doctors, hospitals, and other care providers that need testing support but do not run their own full laboratory network. What sets Medicover apart is that it sits in the middle of the healthcare chain, combining its own care centers with its own testing network. That gives it control over both diagnosis and treatment, helps keep patients inside its system, and gives recurring revenue from long-term clinic memberships and repeat testing rather than one-time sales.
Medicover AB is a private healthcare and diagnostics company that runs clinics, hospitals, specialty centers, and medical labs. It serves patients directly, as well as employers, insurers, and other healthcare providers that buy testing or care for their members and employees. The company’s main services are doctor visits, specialist treatment, preventive care, fertility and women’s health services, and lab and imaging tests.
Medicover makes money in two main ways: patients pay out of pocket or through insurance for medical visits and procedures, and business customers pay for diagnostic testing and corporate health plans. Its diagnostics business also sells lab services to doctors, hospitals, and other care providers that need testing support but do not run their own full laboratory network.
What sets Medicover apart is that it sits in the middle of the healthcare chain, combining its own care centers with its own testing network. That gives it control over both diagnosis and treatment, helps keep patients inside its system, and gives recurring revenue from long-term clinic memberships and repeat testing rather than one-time sales.
Record Results: Medicover delivered its best quarterly report since listing, with strong top-line growth and significant margin expansion across most business units.
Margin Expansion: EBITDA margin increased by 1.6 percentage points and EBIT margin by 2.4 percentage points, showing clear operational leverage.
India Weakness: The Indian business had a disappointing quarter due to weak consumer sentiment and halted medical tourism, but management expects a return to strong double-digit growth in April.
Diagnostic Strength: Diagnostics division saw robust organic growth and margin improvement despite pricing pressures in Germany’s public sector; private pay in Germany is growing rapidly.
Financial Targets Achieved: On an annualized basis, Medicover has already met or exceeded its ambitious 2025 year-end financial targets with three quarters to spare.
Accretive M&A: Two recent acquisitions—SYNLAB assets and a fitness operator in Poland—are expected to be highly accretive, adding about EUR 80 million in annualized revenue.
Cash Flow & Leverage: Strong cash flow continued, and leverage improved to 3x, with management expecting a temporary rise in Q2 due to acquisitions before returning below 3x by year-end.
